You are here

Lupin Pharmaceuticals Issues Recall of Ceftriaxone for Injection USP

Injecting Corrupted Drug Could Cause Phlebitis, Pulmonary Embolic Events

After finding grey particulate matter in reconstituted vials, Lupin Pharmaceuticals, Inc. issued a voluntary recall to the hospital/physician level of 5 lots of Ceftriaxone for Injection, USP, 250 mg; 10 lots of Ceftriaxone for Injection, USP, 500 mg; 24 lots of Ceftriaxone for Injection, USP, 1 g; and 3 lots of Ceftriaxone for Injection, USP, 2 g.

Incorrect piercing and using a needle greater than 21 gauge while reconstituting the vial can force rubber flecks from the stopper into the solution. There were no grey flecks seen prior to reconstitution of the vials.

Injecting ceftriaxone (with the rubber particles) could result in vein irritation/phlebitis or pulmonary embolic events that could lead to permanent impairment of body function or damage to, for example, the lungs and vascular system. Also, as the drug can be administered intramuscularly, its use may cause local muscle inflammation and/or abscesses.

Ceftriaxone for Injection, USP, is a sterile, semi-synthetic, broad-spectrum cephalosporin antibiotic for intravenous or intramuscular administration. It is used to decrease the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone sodium and other antibacterial drugs. The drug should be used to treat or prevent only those infections either proven or believed to be caused by bacteria.

Ceftriaxone for Injection, USP, is packaged in glass vials, in packs of 10, containing 10 vials in a carton, with NDC 68180-611-10, 68180-622-10, 68180-633-10, 68180-644-10 and as single pack containing one glass vial in a carton with NDC 68180-611-01, 68180-622-01, 68180-633-01.

Lupin Pharmaceuticals Inc. is notifying distributors and arranging for the return of all recalled product lots. The recall is being conducted with the knowledge of the FDA.

Source: Drugs.com, January 5, 2019

Recent Headlines

Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs